W L Gore & Associates recalled over 52,000 vascular grafts on August 26, 2025, due to reports of delamination. The defect can lead to severe complications such as bleeding or cannulation difficulties. Affected products include multiple model numbers, which were distributed across the United States and internationally.
Reports of vascular graft delamination, which may lead to reduced access flow; cannulation difficulties; bleeding or bruising; and harms related to reintervention procedures, so Instructions for Use will be updated to modify existing warning to 1) further clarify techniques that may contribute to the risk of delamination, 2) Addition of delamination to device-related adverse event section.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact W L Gore & Associates, Inc. or your healthcare provider for instructions. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall affects GORE ACUSEAL Vascular Grafts with reference numbers including ECH050020J, ECH050050W, and ECH060040. These devices were sold to healthcare providers and facilities in the U.S. and multiple countries including Canada, Germany, and the United Kingdom.
Reports indicate that delamination of the vascular grafts may result in reduced access flow, bleeding, and complications requiring further medical intervention. The FDA classified this recall as Class II, indicating a potential for serious adverse health consequences.
There have been no specific incident or injury counts reported in the recall notice. However, the potential risks include serious complications related to cannulation difficulties and the need for reintervention.
Patients and healthcare providers should immediately stop using the device. Follow the recall instructions from the manufacturer and contact W L Gore & Associates, Inc. for further guidance.
For assistance, contact W L Gore & Associates, Inc. directly. Visit their website or refer to the recall link for more information.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.